Boone Capital Management LLC is an SEC-registered investment adviser based in Atlanta, GA that reports managing 1 hedge fund on Form ADV. It reports $963.2 million in regulatory assets under management. Its private funds, of all types, hold $963.2 million in gross assets. Its disclosed U.S. stock holdings returned an estimated +19.5% 2026 YTD through Jun 30 (S&P 500: +9.5%), based on 13F filings. Over a longer period they returned an estimated +49.3% from Q3 2024 to Q2 2026, compared with +37.2% for the S&P 500, based on 13F filings.
- Regulatory assets under management
- $963.2 millionForm ADV Item 5.F
- Gross assets of private funds
- $963.2 millionAll private fund types, Form ADV
- Hedge funds managed
- 11 private funds in total
- Employees
- 5Form ADV Item 5.A
- Registration
- SEC-registered adviserCRD 316230
- Latest Form ADV
- 03/30/2026Disciplinary disclosures: none reported
Estimated 13F portfolio performance
Estimated by AltMountain, derived from the firm’s public Form 13F filings. Not reported by the firm and not the return of any fund.
| Quarter | Est. 13F return | S&P 500 |
|---|---|---|
| Q2 2026 | +11.9% | +14.8% |
| Q1 2026 | +6.7% | -4.6% |
| Q4 2025 | +16.4% | +2.4% |
| Q3 2025 | +7.5% | +7.8% |
| Q2 2025 | -4.6% | +10.4% |
| Q1 2025 | -0.9% | -4.5% |
| Q4 2024 | -5.4% | +2.1% |
| Q3 2024 | +11.7% | +5.4% |
Estimate of the firm's disclosed long U.S. stock portfolio from its quarterly 13F filings, holding each quarter-end portfolio to the next quarter-end at prices implied by all 13F filers. It is a price return before dividends and fees, ignores shorts, options, bonds, cash and trading within the quarter, and is not the return of any fund. Disclosures
Manager of this firm? Report your fund’s actual net return, or email hello@altmountain.com to correct or remove this estimate. Removal requests from the firm are honored.
13F holdings as of Sep 30, 2026
All 16 share positions ($376,702,434) reported by Boone Capital Management LLC on Form 13F for the quarter ended Sep 30, 2026, filed Nov 16, 2026. Shown as filed with the SEC. Original filing on SEC.gov ↗ The estimated return above runs through Jun 30, 2026; it is updated when the SEC publishes its complete data for the quarter.
Share of the reported 13F portfolio, ten largest positions
- Biomarin Pharmaceutical Inc10.70%
- Teleflex Incorporated9.59%
- Mirum Pharmaceuticals Inc9.43%
- Unitedhealth Group Inc8.64%
- The Cigna Group8.10%
- Guardian Pharmacy Svcs Inc7.85%
- Avantor Inc7.35%
- Labcorp Holdings Inc7.16%
- Encompass Health Corp6.64%
- Vestis Corporation5.62%
| Stock | Value | % of 13F portfolio | Shares | Shares vs prior quarter |
|---|---|---|---|---|
| Biomarin Pharmaceutical Inc | $40,319,880 | 10.70% | 671,998 | +15.22% |
| Teleflex Incorporated | $36,123,931 | 9.59% | 288,899 | -25.42% |
| Mirum Pharmaceuticals Inc | $35,528,993 | 9.43% | 415,641 | Unchanged |
| Unitedhealth Group Inc | $32,555,224 | 8.64% | 88,687 | Unchanged |
| The Cigna Group | $30,517,810 | 8.10% | 112,268 | -29.52% |
| Guardian Pharmacy Svcs Inc | $29,567,988 | 7.85% | 725,061 | +1.84% |
| Avantor Inc | $27,676,529 | 7.35% | 1,838,972 | New |
| Labcorp Holdings Inc | $26,975,339 | 7.16% | 87,551 | New |
| Encompass Health Corp | $25,007,259 | 6.64% | 205,838 | New |
| Vestis Corporation | $21,157,591 | 5.62% | 1,583,652 | -16.66% |
| Pennant Group Inc | $20,510,724 | 5.44% | 525,916 | +1.96% |
| Bridgebio Pharma Inc | $18,255,091 | 4.85% | 277,433 | -18.33% |
| Waystar Hldg Corp | $12,889,166 | 3.42% | 508,649 | New |
| Cullinan Therapeutics Inc | $10,603,995 | 2.81% | 690,814 | -1.93% |
| Maze Therapeutics Inc | $4,878,674 | 1.30% | 179,495 | New |
| Adlai Nortye LTD | $4,134,240 | 1.10% | 258,390 | Unchanged |
Changes since Jun 30, 2026
Comparing the share counts in the two quarter-end filings: 5 new positions, 5 sold out, 3 increased, 5 reduced and 3 unchanged.
Number of positions (a count, not dollars)
- New positions5
- Increased3
- Unchanged3
- Reduced5
- Sold out5
New positions
| Stock | Value | Shares |
|---|---|---|
| Avantor Inc | $27,676,529 | 1,838,972 |
| Labcorp Holdings Inc | $26,975,339 | 87,551 |
| Encompass Health Corp | $25,007,259 | 205,838 |
| Waystar Hldg Corp | $12,889,166 | 508,649 |
| Maze Therapeutics Inc | $4,878,674 | 179,495 |
Sold out
| Stock | Value at Jun 30, 2026 | Shares held then |
|---|---|---|
| Ionis Pharmaceuticals Inc | $41,228,976 | 519,977 |
| Monte Rosa Therapeutics Inc | $14,889,945 | 615,287 |
| Kodiak Sciences Inc | $14,727,270 | 378,010 |
| Tango Therapeutics Inc | $14,242,212 | 455,605 |
| Kymera Therapeutics Inc | $12,977,548 | 113,173 |
Largest increases
| Stock | Change in shares | Change | Value now | Shares now |
|---|---|---|---|---|
| Biomarin Pharmaceutical Inc | +88,779 | +15.22% | $40,319,880 | 671,998 |
| Guardian Pharmacy Svcs Inc | +13,122 | +1.84% | $29,567,988 | 725,061 |
| Pennant Group Inc | +10,098 | +1.96% | $20,510,724 | 525,916 |
Largest reductions
| Stock | Change in shares | Change | Value now | Shares now |
|---|---|---|---|---|
| The Cigna Group | -47,022 | -29.52% | $30,517,810 | 112,268 |
| Teleflex Incorporated | -98,489 | -25.42% | $36,123,931 | 288,899 |
| Vestis Corporation | -316,488 | -16.66% | $21,157,591 | 1,583,652 |
| Bridgebio Pharma Inc | -62,287 | -18.33% | $18,255,091 | 277,433 |
| Cullinan Therapeutics Inc | -13,628 | -1.93% | $10,603,995 | 690,814 |
Each list shows up to 20 positions, largest first by dollar amount. Changes compare two quarter-end snapshots, with the earlier share count adjusted for stock splits AltMountain detected. They do not show when, or at what price, anything was bought or sold.
From public Form 13F filings, not verified. Form 13F is filed up to 45 days after the quarter ends, so positions may have changed. It lists only certain long positions in U.S.-listed stocks and exchange-traded funds; options are not shown here, and short positions, most bonds, cash, non-U.S. securities and private investments are not reported at all, so a holding may be one side of a hedge. A filing covers the manager as a whole, not any single fund, and filings contain errors. This is not investment advice or a recommendation to buy or sell any security. Disclosures
Hedge funds filing Form D (2)
Matched to this firm by the fund names and related persons in each Form D. The list may be incomplete.
Private funds reported on Form ADV (1)
As reported in the adviser's Form ADV filed Mar 27, 2024. Funds also listed from Form D are shown above.
From SEC filings. Firm data comes from the SEC's Form ADV data as of Oct 2, 2026; performance estimates come from Form 13F. AltMountain has not verified this information, and it is not an offer, solicitation or recommendation. Full disclosures